Workshop recommendations by Swan, Patricia B.
WORKSHOP RECOMMENDATIONS
HERBICIDE TOLERANCE IN CROPS
Concentrating on four priority issues and goals, this workshop made the 
following recommendations:
HTCs and herbicide use—There was general agreement that the pri-
mary goal of research should be to ensure that HTCs result in the safer use 
of safer herbicides. Additionally, farmers must learn how to integrate the 
various options for weed control into the best management plan for their 
farms.
Conduct field research studies that compare alternative weed control strate-
gies, including how HTCs will affect the overall production system.
Focus HTC research on herbicides with the following attributes: low toxicity 
to non-target species, including humans and wildlife; low residues in the 
environment, including groundwater, surface water and air; nontoxic 
residues in crops and food; low use rates; appropriate degradation to be-
nign breakdown products; cost effectiveness; compatibility with alterna-
tive weed management strategies; compatibility with technology improve-
ments in the way herbicides are applied; and increased reliability of weed 
control accompanied by improved crop yields.
Health and environmental risk assessment—There was agreement 
that any risks need to be identified, and criteria to assess these risks devel-
oped. The federal government should:
Evaluate environmental data for HTCs on a case-by-case basis and in a rea-
sonable timeframe.
Use public funds to construct a data base from information obtained from 
small scale field trials.
Provide guidance to ensure that seed companies and other institutions devel-
oping HTCs ensure the food safety and quality of the crops. 
Socioeconomic Impacts—Government institutions that currently deal 
with socioeconomic concerns should:
Consider the impact of HTCs and, if appropriate, mitigate any impacts. 
Foster public discussions on the impacts of HTCs, including socioeconomic 
impacts.
It was agreed that socioeconomic impacts of HTCs should not be a 
“fourth criterion” for regulatory approval of a product for commercializa-
tion—the products should be judged on three criteria: human and envi-
ronmental safety, quality and efficacy.
Regulatory Policy—Participants felt that the impact of regulations on the 
cost of products and the development of minor versus major crops must 
be considered. A fair, timely process clarifying or establishing regulatory 
policy is needed. The federal government should:
Articulate a policy stating what is regulated and who regulates by January 1,
1992. Within a reasonable time after a regulatory policy has been ar-
ticulated, it should be “tested” with a specific HTC ready to go through 
such a process. Three general criteria for this process were set: l- pro-
vide meaningful opportunities for public input; 2- allow industry to 
proceed in a fair and timely manner; and 3- as appropriate, responsible 
health and environmental safety reviews should be conducted.
BIOLOGICAL CONTROL OF PESTS
Out of four subgroups identified, (technology, regulation, commercializa-
tion and adoption), four issues emerged as important for the develop-
ment and increased application of biological control in the coming years. 
First, because of a lack of leadership, biological control must get on the na-
tional agenda. For this to happen, advocacy is necessary from academi-
cians, legislators and other public policy makers.
Second, effective and reasonable regulatory procedures are needed.
Third, a tax on pesticides should be established to provide government rev-
enues for the promotion of biological control applications.
Fourth, an increase in government funding in the public arena (research 
and extension) and the establishment of (financial) incentives for an in-
crease in supply (industry) and demand (farmers) of biological control 
is necessary.
Each subgroup in the workshop developed specific recommendations: 
Technology—Establish and maintain basic and applied research programs 
to address scientific issues. In order of priority, research programs 
should focus on: 1- host-pest biocontrol agent interactions; 2-ecologi- 
cal relationships between the target pest, its environment and biologi-
cal control agent; 3-host resistance mechanisms; and 4-compatibility
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of biological control agents with chemical agents in integrated pest 
management programs.
Provide public funding and incentives for ‘public good’ (commercial prod-
ucts) types of biological control.
Provide incentives for ‘private good’ types of biological control. Among the 
variety of options discussed with no consensus: diverting money from 
the Clean Water Act; a pesticide tax; an “Orphan Drug Act” for small 
market biopesticides; R&D tax credits; lowering capital gains taxes to 
help R&D investments; and regulations for field testing and registra-
tion of biocontrol agents that are clear and concise.
Regulation—In order of priority:
Redefine regulatory procedures by defining agency responsibility for organ-
ism groups; define criteria/characteristics representing risks and benefits, 
and establishing a fixed time for regulatory decisions to on-field test appli-
cations.
Improve communication by facilitating access to federal and state regulatory 
procedures, by establishing voluntary mechanisms to share the results of 
safety tests between investigators and between federal and state authori-
ties (such as the National Biological Impact Assessment Program 
(NBIAP)data base in the USDA).
Commercialization—Incentives to increase use of biolocies and mini-
mize the current barriers are necessary:
Set up national research centers to develop biological control methods with 
locals and cooperatives, and create a clearinghouse for basic and applied 
information on the delivery of biological control agents.
Modify crop support programs to encourage diversification and provide in-
surance premiums against crop loss to farmers who use biological control 
agents.
Develop programs to change the lack of tolerance for imperfections at all lev-
els of the marketing system.
Adoption and Implementation—Establish a national program pro-
moting biological control which includes developing educational and in-
formational materials and their distribution, and establish demonstration 
projects on farms.
Establish programs to reduce the initial cost disadvantage of biological con-
trol agents over traditional pest management techniques, possibly includ-
ing taxing pesticides!users and use of the revenues for these programs.
Agricultural Biotechnology at the Crossroads
TRANSGENIC ANIMALS
Four general areas were identified for discussion:
Unintended and unwanted consequences —Listed were: 1- the impact on 
genetic diversity, animals as disease vectors and effects upon wild 
populations as well as pollution that maybe associated with animal 
production; 2- the well-being of the animals themselves, both in terms 
of their health and their ability to lead relatively tranquil lives; and 3- 
consequences not readily anticipated.
Conduct animal genetic research to enhance human and animal well-
being at an acceptable risk to animals, humans and the environment. 
Strategies expected to achieve this goal: 1- sufficient public funds to 
conduct research in the area of transgenics, thereby reducing the pres-
sure to rush to market and to support research on risk; 2- the use of 
peer review panels, such as current animal care committees, to assure 
proper procedures are used by researchers and the public is made aware 
of these procedures and has the opportunity to express concern to the 
appropriate bodies; and 3- the development of model systems to an-
ticipate both unwanted and beneficial outcomes of transgenic research.
Socioeconomic concerns—In order to minimize the negative and maxi-
mize the positive socioeconomic impacts of transgenic animals and their 
products at the local, national and international levels, four key steps 
were identified: 1- determine the type of transgenic animal or product, 
the time frame in which it will be developed and adopted, and where 
and how it will be used; 2- identify direct economic consequences 
(good and bad) of adoption, including downstream second and 
third-order consequences; 3- identify possible associated environmen-
tal benefits/costs; and 4- identify segments of world society that are af-
fected by transgenic animal technology.
Funding—Since transgenic technology is merely a tool, it should not be 
singled out as a special priority for funding. Rather, basic animal ge-
netic research funding should be increased in order to increase the genetic 
knowledge base.
Food safety and consumer acceptance—Participants felt that the ex-
isting research and regulatory systems need to be more effective in 
building public communication, confidence and acceptance of food 
derived using biotechnology. To this end:
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Meet consumer needs with enhanced quality and safety of products. 
Consult the public early in the research and production process to deter-
mine consumer acceptance of products.
Use biotechnology to assure food safety and quality.
Enhance the credibility of the regulatory system.
Expand dialog with the public and in K-12 and college classrooms.
Discuss the results of safety and socioeconomic research publicly.
ANIMAL GROWTH PROMOTANTS
While workshop participants identified several important issues and
goals, there was a divergence of opinion on how they might be addressed.
The following recommendations were presented:
Assess the broader social impact of animal growth promotants (and all new 
technologies). There was disagreement as to how, what, by whom and 
when. This was the most controversial issue discussed.
Assess the process by which AGPs are regulated for human, animal and envi-
ronmental safety for possible improvement. The methodology proposed 
to accomplish this goal includes: 1- identifying the concerns of the dif-
ferent constituencies, possibly in a meeting or via a survey; 2- briefing 
these groups on the regulatory process as they each may not have a 
complete overview of the process; 3- developing a white paper that re-
flects the concerns of the groups with subsequent feedback in order to 
reach a consensus; and 4- developing solutions for the concerns identi-
fied.
Make information available on the risks and benefits of AGPs. The method-
ology proposed included: 1- research to determine potential risks and 
benefits; 2- public education to disseminate this information; and 3- 
public policy set to insure that relevant, credible, objective, 
non-proprietary information would be available to all.
Eliminate international regulatory disparities with a goal of (free/fair) trade. 
To accomplish this: 1- establish an international dispute settlement 
mechanism such as GATT; 2- conduct research in a neutral, indepen-
dent setting such as an international research center; establish objective 
international standards such as CODEX; and 3- educate consumers 
possibly using UN/FAO funds.
Agricultural Biotechnology at the Crossroads
TYING IT ALL TOGETHER
As I reflect aloud for the next few minutes on my impressions of the meet-
ing that we have just been through together, I ask that you reflect on your 
impressions as well. Obviously, our reactions to the meeting come out of 
the experience and perspective that we bring to 
the meeting and your reactions will be some-
what different from mine.
I want to do two things. First, to review the 
theme of the meeting, agricultural biotechnol-
ogy at the crossroads and use that to talk about 
what we have heard and said together; and sec-
ond, to spend a few minutes reflecting on the 
actual way in which we met together and the 
quality of our communication.
The call to the meeting elaborated the theme of 
the meeting. To remind you, “In the late 1970s, 
several published reports emerged extolling the 
benefits of biotechnology, predicting the out-
come of exciting new research agenda, antici-
pating the potentially vast benefits.. .Biotechnology became the byword of 
the 1980s, with new techniques for mediating the determinants of hered-
ity, almost anything seemed possible. These new techniques were expected 
to raise agricultural productivity while reducing chemical use in agricul-
ture, thus leading to a cleaner, healthier environment. These predictions 
reflected the tenor of the times, in which biotechnology was widely held to 
be a technology that would revolutionize the coming decades.” Not sur-
prisingly, this point of view was expressed optimistically. It was a critical 
juncture, I would assert, a time when we were trying to interest investors 
of all types in the promise of these new technologies. We (scientists) were 
going to Congress and to the public, and quite unusually, to venture capi-
talists. The science of molecular biology was giving rise to these new tech-
nologies but the question remained “Could the resources be found to de-
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velop these technologies?” Promises were made at this juncture and like 
many promises, they sometimes come back to haunt us.
I am reminded of a story Garrison Keillor told the other day. He was 
talking about a particularly life threatening critical juncture and he found 
himself beginning to pray. “God, if you will just help me out of this prob-
lem, alive, then remember those promises I made to you back in Chicago 
at O’Hare when the landing gear didn’t go down on the airplane...?” Thus 
the old promises came back to haunt him.
One speaker, Roger Salquist, disputed the premise that the promises 
have failed to develop as predicted. Instead, he asserted that biotechnol-
ogy to date has met the knowledgeable predictions that were made 10 
years ago and that we are now on the verge of having an impressive portfo-
lio of products.
The call to the meeting went on to say, “Clearly, complex, unforeseeable 
biological, institutional and socioeconomic changes have emerged that 
place biotechnology in a new context. Today, constraints and incentives 
create an environment for research and application that is very different 
from the rules and regulations perceived to constrain both scientific and 
public policy development ten years ago. This Third Annual Meeting will 
assess the reasons why many biotechnology innovations have failed to de-
velop as predicted, identify and evaluate the constraints and incentives 
that currently drive research, commercialization and acceptance of bio-
technology products and seek ways to assess their appropriateness or in-
appropriateness.”
Appropriate to the theme of the meeting, several crossroads have been 
set before us. As we meet these crossroads, the question is “Will the direc-
tion we choose give fulfillment to the promise that biotechnology will in-
deed revolutionize the era ahead?” or, “As we meet these crossroads will we 
find that we were wrong about the promises of biotechnology?” During 
the last two days, several types of crossroads were discussed, not just the 
major one suggested by the call to the meeting, but several smaller cross-
roads within that. Some of the larger intersections are behind us. It is al-
ways good to reflect on the roads crossed in the past and the decision 
made to take a certain direction. I would assert that we have already 
crossed at least three crossroads.
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CROSSROADS PASSED
Ten years ago, there were many different definitions of biotechnology. The 
word was used to signify different kinds of activities and enterprises and 
was used in many different ways. During the last two days, several people 
offered definitions as if they still wanted to clarify, but their definitions 
agreed. There was a consensus that biotechnology is a set of technologies, 
a set of tools, a set of methods and not a monolithic entity.
Another crossroad we have passed is the question of whether or not 
these technologies will be used in agricultural science. We have lots of evi-
dence that we are beyond that question—they are being used now and 
they will be used in the future.
A third crossroad that we have passed is the question of whether or not 
to regulate the products of biotechnology. Ten years ago, some people said 
“They are like natural products, don’t bother to regulate.” and there were 
others who said, “They are VERY unnatural products, regulate everything 
about biotechnology.. .the process, all the products, etc.” We have come to 
that crossroad and for a variety of reasons are agreeing that we will regu-
late only the products of biotechnology. No longer is there any sizeable 
voice suggesting no regulation at all.
FUTURE CROSSROADS
There are several crossroads we still face. We have come upon them, but 
we have yet to make decisions on which way to go. Over the last two days, a 
major crossroad permeating much of the discussion at all levels from the 
general to the highly specific was the question of whether biotechnology 
will drive our future. Are we going to be led by the technology, caught up 
in it, or carried along by it? Or, as some of our speakers have asserted, will 
other forces set the direction for us and determine the way in which we use 
these technologies that we call “biotech”? Which will be the driving force?
Forces proposed were economic forces of varying types, including in-
ternational trade; the risk-benefit issues for farmers, consumers, etc.; and 
the developing and overriding environmental concerns in our society to-
day. The question is “What other factors will be allowed to drive biotech-
nology if we do not allow the technology to determine our future?” There 
is no agreement yet. Some would say the technology should have free 
reign, while others would say that economics should be the overriding
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concern. Still others would say there are social concerns which must then 
modify our economic system. It seems there is considerable disagreement 
arising from the differing values we bring to the table, as to what the role 
should be of these other forces which may determine the future use of 
biotechnology.
There are other crossroads which received attention. I had not pre-
dicted that regulation would be as pervasive an issue as it was in the last 
two days. Throughout the workshops, as well as in the informal discus-
sions here together, regulation seemed a compelling topic. I heard agree-
ment on the point that regulations should be fair, timely and there should 
be a great deal of public trust in it. I heard some agreement that regulation 
is not perfect yet. I heard much disagreement as to its points of imperfec-
tion. Clearly we have had too little dialog on how to regulate, who regu-
lates whom and what. I found a lot of consensus that we should have some 
regulatory activity to assure safety. We do not seem to agree whether effi-
cacy is an important point in regulation. Currently some products in our 
market are judged by whether or not they are efficacious, while others are 
not. Where biotechnology products should lie within the whole regula-
tory scheme is a point over which we have yet to reach a consensus.
We also disagreed on how well we are doing—I heard one speaker say 
that he thought there was considerable room for improvement and he fo-
cused on the complexity and uncertainty on the multitude of organiza-
tions involved in regulation. Another speaker said he thought it was going 
very well - that his own experience with the regulatory process had been 
extremely smooth, processing had gone in a timely fashion and that he 
was anticipating nothing but the best. In the unknown time ahead we will 
look at the regulation of actual products coming to market, commercial-
ization as opposed to field trials and testing stages of development of 
products. The commercialization of products will precipitate many diffi-
cult regulatory decisions.
In sum, I heard more concerns about points of imperfection in the 
regulatory system than I heard agreement that it was doing well. Although 
a lot of regulatory sub-issues were explored in the workshop reports, it 
would be redundant to summarize them again this morning.
Let me comment on a couple of other areas where I think I heard some 
agreement. They are old questions. Should we be regulating the science
Tying It All Together 19
that is behind these new technologies? There was not quite 100 percent 
agreement, but a fair consensus that we should not regulate the science per 
se. We should regulate the products of the technology arising from the sci-
ence, and while we agreed to regulate the products, we disagreed as to the 
criteria we should use. The unmapped territory ahead has given rise to a 
lot of uncertainty and feelings of insecurity, heightening the need for 
more exploration of what it is that we are going to be doing in the process 
of regulating products as they are commercialized.
Funding was another crossroad that came up throughout the meeting.
It was amazing to me that it came up as frequently as it did. Although 
funding is part of my job, a part of my business, I had not imagined that 
funding could be so broad a concern as it appears to be in this meeting. 
Dollars. Whose dollars? There was much discussion about the role of pub-
lic funding and private funding. The kinds of activities which face us in 
developing products from biotechnology give rise to the questions, “What 
should be the role of public funding? What should be the role of private 
funding? Do they have different roles?” This is not a discussion limited to 
biotechnology, but the kind of questions that arose suggested that we need 
much more discussion of funding, especially since there is not an under-
standing among us about what our position is on the roles of public and 
private funding. There are many questions about the appropriateness of 
different kinds of work using public or private funds, as well as questions 
about how these funds are currently being used. Again there is room for a 
lot more discussion and a chance to get much more highly specific about 
what it is that concerns us in these arenas.
Funding for commercialization also came up. I was surprised that it did 
not come up more often. I had predicted that it would come up more be-
cause the press is writing a lot about where we are with regard to funding 
for biotechnology companies, both biomedical and agricultural 
biotechnology.
There was a lot of discussion about the myriad lists of critical technolo-
gies that are emerging from Washington and related groups; discussion 
about the current state of competitiveness in biotechnology and what we 
can expect in the future. Those emerging lists are saying that we are cur-
rently very competitive in biotechnology in the United States as compared 
to the rest of the world, but that funding concerns, especially for commer-
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cialization of products, as well as regulatory and other concerns, are giv-
ing rise to questions about how long we will remain competitive. These 
are all popular issues in the press today; however, there was not as much 
about these issues at our meeting as I had anticipated. “How critical are 
these issues?” presented another crossroad on which we expect to differ.
Other crossroads.. .what type of research should we be doing? Who de-
cides? “Who decides” kept coming up and not getting answered, except 
“ME, I’ll decide.” Whoever is talking is the person who wants to decide. It 
is an important issue, one needing some public understanding and con-
sensus. What decisions are appropriate in the public arena? What are ap-
propriate in the scientific arena? How do those two inform each other as 
they each make their appropriate decision? Again, we have not had 
enough dialog on these issues because I heard more questions than I heard 
any attempts to provide answers or even points of view.
The technologies we have been discussing for the last two days are de-
veloping extremely rapidly. We are making remarkable progress in bio-
technology, but it maybe that the technology has outstripped our basic 
knowledge with regard to biological systems. What limits us in our ability 
not only to use these technologies, but to use them wisely, is the fact that 
we do not have enough knowledge of the biological systems in which we 
are using them. This limitation came up in many different ways during the 
meeting. There was a strong call for getting on with the business of under-
standing these biological systems more clearly so that we can be more 
thoughtful about what we are doing with technology. There seemed to be 
a pervasive concern that we have outstripped our ability to assess impacts 
of the technology. We are not skilled at assessing those impacts. We all say 
we worry about them, and I think we do. We agree that we worry about the 
social impacts, economic impacts and other kinds of unforeseen conse-
quences of these new technologies. We are uneasy because we do not know 
if we can successfully assess the future. We are uneasy because we do not 
know if we will take the time to do it, and we do not know who will do it. 
These are points about which we have a great deal of unease. From discus-
sions, it seemed there was more concern and unease than disagreement or 
conflict. We do not yet know where we each have positioned ourselves 
within this whole arena. Thus there also looms a crossroads with regard to 
our research agenda, not only funding or the type of research we are do-
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ing, but also what we need to do in order to make ourselves better able to 
assess the impact of these technologies.
Communication was another pervasive concern, but I do not know if 
“communication” could ever be considered a crossroads. We almost al-
ways refer to it as a two-way street or many two-way streets. Communica-
tion is certainly something that everyone was worrying about. We agreed 
that we wanted to communicate. We agreed that we wanted to communi-
cate better. We seem to agree that our communication is not as good as it 
should be. It is typical of society today that we have this concern. Unfortu-
nately, we did not have the time to explore how we could improve com-
munication. What could we do, specifically, to improve our communica-
tions, improve it in the regulatory arena, improve it in the research-deci-
sion-making arena, improve it in the funding arena? There were many 
places where we asked for improvement, but did not really explore what 
we were doing wrong or not enough of, or should be doing more of, to im-
prove communication. The issue of education came up frequently... edu-
cation that would provide a more common understanding on which to 
base our communication and education to improve decision making. 
There was a strong call for more exchange of information, an open ex-
change of information and lots more of it.
HOW DID WE DO?
Those are some of the crossroads that I heard being discussed in the last 
two and half days. How did we discuss them? NABC has the goal of bring-
ing together diverse views, openly discussing and examining those diverse 
views and in Ralph Hardy’s words, “We’re coming together to speak, to lis-
ten, to learn.” How well did we do that? I offer special thanks to the NABC/ 
Joyce Fellows, because I asked them at some length last night how well 
they felt we had achieved this goal. They had a fairly optimistic answer for 
me. They seemed to feel that we had a good diversity of views. Here they 
mentioned two perspectives which they were not sure were represented as 
well as they should be. Regulators were one group. Another group whose 
view they thought was missing was the farmers who will actually employ 
these technologies. But they felt that the discussion had been open and 
that there had been an exchange of the many views present here. On those 
grounds, they were rather optimistic about the goal of the meeting being 
achieved.
Swart
I always ask, “How vigorous and how fearless was our examination of 
issues?” Those of you associated with the University of Wisconsin know 
about one of the formative statements behind the University which has 
touched all of us at UW. It is a statement on a plaque in the main adminis-
tration hall there. It comes from a statement made by the Wisconsin Board 
of Regents before the beginning of this century: “In all lines of academic 
investigation, it is of the utmost importance that the investigators should 
be absolutely free to follow the indication of truth, wherever they may 
lead. Whatever may be the limitations which trammel inquiry elsewhere, 
we believe that the great state University of Wisconsin should ever encour-
age that continual and fearless sifting and winnowing by which alone the 
truth can be found.” I heard some fairly courageous sifting and winnow-
ing in the last two days, although I am not sure it measured up to the stan-
dards set by Wisconsin’s Regents 100 years ago.
Perhaps we were not completely fearless. We may not have been willing 
to voice our opinions as strongly and with the conviction that is required 
to really examine perspectives and to push to a true consensus. We can ex-
cuse ourselves, for in two days what can you do? We can excuse ourselves 
because we are all nice people and we do not want to hurt other people’s 
feelings. We can excuse ourselves for a variety of reasons. However, from a 
professorial tradition, I would have to say in that regard that I think the 
best grade we could give ourselves would be a B.
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POST MEETING SUMMARY
In a post-meeting session, members of the NABC Council and Operating 
Committee, NABC/Joyce Fellows and Graduate Fellows, speakers, workshop 
chairs and session moderators came together to discuss the meeting and its 
recurrent themes and to develop a follow-up strat-
egy for NABC and its member institutions.
Following lively debate, three priority action 
areas were identified:
1 - the need for adequate funding to further de-
velop our national research capacity with strong 
support for stepwise increases over 5 years to 
full funding of $500 million for the National Ini-
tiative for Research on Agriculture, Food and 
Environment.
2-the need to include a more substantive social and economic impact 
assessment in all technology impact assessments of emerging agricul-
tural biotechnology applications.
3 - concern about the need for additional regulatory definitions as well as 
what the appropriate level of regulation by the federal government should 
be and the role of individual states.
As an initial step, letters prepared with input from designated attendees 
were sent from NABC to appropriate Congressional members and agency 
officials. The strength of these recommendations lies in the backing they have 
received from participants with different interests and agendas who came 
together at NABC3 to promote current, specific needs in agricultural biotech-
nology.
JUNE FESSENDEN
MACDONALD 
Deputy Director 
NABC
159 Biotechnology Bldg. 
Cornell University 
Ithaca, NY 14853
